Cure My Disease

Don't miss your cure!

 Log in / Sign up

Grape seed extract may tame High-Normal blood pressure

NCT ID NCT07090876

Disease control Sponsor: Indena S.p.A Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a grape seed extract can lower blood pressure in 60 adults with high-normal blood pressure (130-139/85-89 mmHg). Participants will take either the extract or a placebo for 8 weeks, while following a low-sodium Mediterranean diet. The main goal is to see if the extract reduces systolic blood pressure more than the placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects aged ≥18 and ≤70 years; * Subjects with high-normal blood pressure levels, defined as SBP 130-139 mmHg and/or DBP 85-89 mmHg (according to ESH criteria); * Subjects with an estimated 10-year CVD risk \<10% (as per the SCORE risk prediction algorithm of the European Society of Cardiology); * Subjects capable of communicating, making themselves understood, and complying with the study requirements; * Subjects who agree to participate in the study and have dated and signed the informed consent form. Exclusion Criteria: * Treatment with direct vasodilator drugs or supplements known to affect blood pressure levels; * Chronic pharmacological treatments for any clinical condition not stabilized for at least 3 months; * Known thyroid, renal, or hepatic dysfunction (including transaminase levels ≥3 times the upper limit of normal \[ULN\]); * Current or past history of alcohol abuse; * Pregnancy or breastfeeding; * Known intolerance or hypersensitivity to the active ingredients of the investigational dietary supplement; * History or clinical evidence of any significant concomitant disease that could compromise subject safety or the ability to complete the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High-normal blood pressure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

High-normal blood pressure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cardiovascular Internal Medicine Unit, IRCCS University Hospital of Bologna, Bologna, Italy

    RECRUITING

    Bologna, Bo, 40100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.